September 15-18, 2025
Hynes Convention CenterBoston, USAKey Sessions
Fouad Atouf
PLENARY KEYNOTE: Evolving Pharmacopeial Standards to Shape the Future of Biological Medicines
US Pharmacopeia
Niklas Engler
PLENARY KEYNOTE: CMC Development - A Key Differentiator for Biotech
F. Hoffmann-La Roche
Amy Shaw
Scale-Out Versus Scale-Up Strategies for Maximizing Cellular Therapies
Takeda, USA
Kelvin Lee
KEYNOTE: The Future of Biopharmaceutical Manufacturing: Innovation and Collaboration
NIIMBL
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Wednesday 17th September - Main Conference Day Two - ET (Eastern Time, GMT-05:00)
keyboard_arrow_leftSearch & Filter
search
Streams
Wednesday 17th September - Main Conference Day Two - ET (Eastern Time, GMT-05:00)
search
Streams
Showing 1 of 1 Streams
Registration Break
7:30am - 8:20am
Registration and Morning Coffee
Showing 6 of 6 Streams
Keynote Plenary
Development of Emerging Cell & Gene Therapies
Cell Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
Innovation and Community Stage (Exhibit Hall)
BioInnovation Group's Executive Summit
8:50am - 9:00am
Welcome to BWB Day 2 / Chairperson’s Opening Remarks
9:00am - 9:40am
PLENARY KEYNOTE: Evolving Pharmacopeial Standards to Shape the Future of Biological Medicines
- Fouad Atouf - Vice President, Science—Global Biologics, US Pharmacopeia
9:40am - 10:20am
PLENARY KEYNOTE: CMC Development - A Key Differentiator for Biotech
- Niklas Engler - Global Head and Vice President, Technical Development Portfolio and Projects, F. Hoffmann-La Roche
8:55am - 9:00am
Chairperson’s Opening Remarks: Development of Emerging Cell & Gene Therapies
- Christopher Bravery, Ph.D. - Consulting Regulatory Scientist, Advbiols
9:00am - 9:30am
Accelerate Manufacturability and Personalize Therapies with Confidential Collaboration
- Kat Kozyrytska - Consultant, Cell Therapy Manufacturability Program
9:30am - 10:00am
Redosable DNA Delivery Systems Designed by Machine Learning
- Shashi Murthy, PhD - CTO and Co-Founder, Nanite Inc.
10:00am - 10:30am
Efficient and Liver-Detargeted In Vivo Multiplex Gene Editing of Human Hematopoietic Stem and Progenitor Cells
- Pauline Schmit - Senior Scientist, nChroma Bio
8:55am - 9:00am
Chairperson’s Opening Remarks: Cell Therapy Manufacturing & Analytics
- Mahesh Bule - Associate Director, Kite Pharma a Gilead Company
9:00am - 9:30am
Scale-Out Versus Scale-Up Strategies for Maximizing Cellular Therapies
- Amy Shaw - Head of Process and Product Development, Takeda, USA
9:30am - 10:00am
TCR-T: Scaling for Success
- Mark Farmery - Chief Development Officer, Anocca AB
10:00am - 10:30am
Bringing Cell Therapy to the Patient—Implementing Decentralized Manufacturing
- Defining point-of-care manufacturing and decentralized manufacturing
- Scaling with consistency: key elements for global standardization
- Tech & innovation: cutting-edge solutions for safe, efficient, and cost-effective decentralized manufacturing
- Overcoming obstacles to decentralised manufacturing to enable access to approved CGTs
- Differences in systems across decentralized cell therapy manufacturing models - how can we harmonize?
- Standardization vs a modular approach
- Equipment, data, and technologies
- Dialogue and collaboration between developer/practitioner to streamline eventual implementation
- Improving worldwide access: how can local manufacturers and supplier help?
- Real world experience with a decentralized cell therapy manufacturing platforms supporting Phase I/II clinical trials
8:55am - 9:00am
Chairperson’s Opening Remarks: Gene Therapy Manufacturing & Analytics
- Francesca Vitelli, PhD - Former VP Cell Therapy and Viral Vector PD and MSAT, Intellia Therapeutics, Inc
9:00am - 9:30am
Keynote Panel Discussion: Strategies for Scaling Up, Accelerating and Commercializing Gene Therapy Manufacturing
- Ying Cai - MSAT Executive Director, Ultragenyx Pharmaceutical
- Nripen Singh - Head of Process Development, TRD CGT, Novartis
- Vaishali Shukla - Vice President, CGT & API Global Expansion, Eli Lilly and Company
- James Warren, Ph.D. - Senior VP, Global CMC Development, Ultragenyx Pharmaceutical Inc.
9:30am - 10:00am
Case Study on Tech Transfer and Scale Up – How to Translate from Small to Large Scale / GMP
- Phillip Ramsey - Senior Vice President, Technical Operations, Sangamo Therapeutics
10:00am - 10:30am
Tech Transfer Best Practices in Gene Therapy
- Jordan Ball - Sr. Manager, Technology Transfer, Regeneron
8:20am - 9:00am
Opening Remarks and "Thinking Outside the Box to Find Solutions"
9:00am - 9:45am
Panel Discussion 1 - The Digital Transformation Journey - Latest Approaches and Lessons Learned from Other Industries
9:45am - 10:30am
Panel Discussion 2 - Investor Perspectives on Navigating Economic Uncertainty and its Impact on Biopharma
Showing 3 of 3 Streams
Break
Innovation and Community Stage (Exhibit Hall)
Poster Viewing - Meet the Poster Presenters
10:30am - 11:25am
Morning Networing Break in Exhibit Hall
10:30am - 10:40am
Accelerating Bioprocess Innovation through Intelligent Automation and Digital Integration
Discover how Yokogawa’s BioPilot transforms bioprocessing with seamless digital integration and intelligent automation. By unifying real-time data acquisition and advanced process control, BioPilot empowers scientists to streamline cell culture and purification workflows—enhancing reproducibility, accelerating development timelines, and enabling effective decisions in cell line, media, and process development.
- Soichiro Shimoda - Bioprocess Development Sect. Manager, Yokogawa Electric Corporation
10:40am - 10:50am
Automated Cell Line Development using DirectedLuck® Transposase: Yield. Quality. Speed.
- DirectedLuck® transposase integrates genes at most active genomic sites via epigenetic targeting and delivers highest pool titers with minimal selection pressure.
- Automated clone assessment enables early clone selection based on platform fit and critical product quality parameters.
- Smart automation delivers better, high quality producer clones in shortest time.
- Volker Sandig - Chief Scientific Officer, ProBioGen AG
10:50am - 11:20am
Tech Showcase
10:30am - 11:25am
Poster Viewing - Meet the Poster Presenters
Explore groundbreaking research, meet the poster presenters and ask your questions.
*For your poster to be entered into the poster competition, please submit your abstract by August 1, 2025 and PDF poster by August 22, 2025*
Showing 10 of 10 Streams
Cell Line Development & Engineering
Cell Culture & Upstream Processing
Downstream Processing
Manufacturing Strategy & Digitalization
Analytical, Quality and Characterization
Development of Emerging Cell & Gene Therapies
Cell Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
Innovation and Community Stage (Exhibit Hall)
BioInnovation Group's Executive Summit
11:25am - 11:30am
Chairperson Remarks: Cell Line Development & Engineering
11:30am - 12:00pm
Removing remaining limitations for plant-based expression of biologicals and unlocking large-scale, commercial-grade cell culture potential
- Andreas Schaaf - CSO & Managing Director, Eleva GmbH
12:00pm - 12:30pm
Enhancing production cell line development through a next-generation sequencing platform
- Xiaodong Sun - Senior Scientist, Takeda
11:25am - 11:30am
Chairperson Remarks: Cell Culture & Upstream Processing
- Yuxin Liu - Scientist, Cell Culture Platform, Sanofi
11:30am - 12:00pm
Next-Gen Upstream Lab: Flexible and Scalable AI Deployment with MLOps
- Shu Yang - Senior Scientist, Pfizer
- Edwin Shen - Principal Scientist, Pfizer
12:00pm - 12:30pm
Unlocking the power of Digital Transformation and AI: a strategy in upstream process development
- Zhuangrong Huang - Senior Staff Engineer, Takeda
11:25am - 11:30am
Chairperson Remarks: Downstream Processing
- Naveen Singh - Principal Scientist II, Process Development, Gilead
11:30am - 12:00pm
The challenge of impurity clearance in a world of complex modalities and high productivities: a case study in low molecular weight (LMW) removal
- Crystal Thomas - Principal Scientist, Purification Process Development, Sanofi
12:00pm - 12:30pm
Harvest Development and Optimization using pDADMAC Flocculation
- Kate Zhao - Scientist I, Upstream Process Development, Alexion, AstraZeneca Rare Disease
11:25am - 11:30am
Chairperson Remarks: Manufacturing Strategy & Digitalization
11:30am - 12:00pm
KEYNOTE: The Future of Biopharmaceutical Manufacturing: Innovation and Collaboration
- Kelvin Lee - Institute Director, NIIMBL
12:00pm - 12:30pm
AI-Enhanced Smart Workflows: Unlocking Speed and Insight in Process Development and Manufacturing
- Mark Duerkop - Chief Executive Officer, Novasign, Austria
11:25am - 11:30am
Chairperson Remarks: Analytical, Quality and Characterization
11:30am - 12:00pm
Ensuring Product Comparability & Accelerating Analytical Method Development: Bridging Early and Late-Phase Development
- Elisabeth Krug - Executive Director, BRD Analytical Development, Eli Lilly & Company
12:00pm - 12:30pm
Defining and Controlling Critical Quality Attributes (CQAs) for Gene and Cell Therapies
- Callum Chapman - Senior Director, Product Quality, AstraZeneca
11:30am - 12:00pm
Leveraging Gene Editing Technologies for Precision and Efficiency in Cell and Gene Therapy Development
- Kristy Wood, PhD - SVP, Technical Operations, Intellia Therapeutics
12:00pm - 12:30pm
Next-Gen Gene Editing – Pushing Boundaries for Enhanced Therapeutics
- Devyn M. Smith - Chief Executive Officer, Arbor Biotechnologies
11:30am - 12:00pm
Revolutionizing Cell Therapy with Automated Manufacturing and Testing Solutions
- Shawn (Xueyuan) Wang - Director, Process Development, Kite Pharma
12:00pm - 12:30pm
Scalable and Cost-Effective Pluripotent Stem Cell Expansion: Enabling Commercialization
- Wonjong Si - Director of Cell Therapy Process Development, Bayer
11:30am - 12:00pm
Revolutionizing Large Scale Gene Therapy Production: Boosting Cell Density and Cell Specific Productivity with Advanced Producer Cell Lines
- Improvements and innovations in cell line development & engineering to increase yields for gene therapies
- Application of producer cell lines to lower transfection vector costs: Data for large scale use of stable cell lines
- Scalability of producer cell lines? Case studies on experiences at larger scales
12:00pm - 12:30pm
Expanding the Upstream Toolbox: Enabling High-Productivity, Robust, and Scalable AAV Production
- Huize Yan - Process Development Scientist, Spark Therapeutics
11:25am - 12:00pm
BPI State of the Industry
Join leading experts for BioProcess Insider's comprehensive analysis of the current bioprocessing landscape, emerging trends, and future directions shaping biopharmaceutical manufacturing and development.
- Dan Stanton - Editorial Director, Informa Connect Life Sciences
12:00pm - 1:00pm
Tech Showcase
11:25am - 12:10pm
Transitioning to CEO
- John Cox - CEO, Dyne Therapeutics
12:10pm - 12:45pm
Stakeholder Roundtable Discussions: Part 1 - Gaining a Deeper Understanding of the Issues (Roundtable Topics to be Determined)
12:45pm - 1:00pm
Lunch and Sponsor Presentations
Showing 4 of 4 Streams
Break
Innovation and Community Stage (Exhibit Hall)
BioInnovation Group's Executive Summit
Live Labs in Exhibit Hall
Live Lab 1:00pm - 2:10pm
Lunch Networking in Exhibit Hall
1:00pm - 1:25pm
Tech Showcase
1:25pm - 1:30pm
Chairperson Opening Remarks: Innovation and Community Stage
- Jared Auclair, PhD - Dean College of Professional Studies and Director of Bioinnovation, College of Science at Northeastern University
1:30pm - 1:50pm
A Fresh Spin on Upstream Processing: Dual-Use Centrifugation for Perfusion and Harvest
As upstream bioprocessing intensifies, efficient cell separation is key. This presentation highlights a collaboration between ProBioGen AG and GEA, showcasing the kytero® Single Use Pharma Separator. Supporting both harvest and perfusion applications, this disk stack centrifuge delivers high separation efficiency at elevated cell densities, reduces process complexity, and integrates seamlessly into intensified CHO-based workflows from pilot to commercial scale.
- Nathalie Rigal - Head of Upstream Process Development, ProBioGen AG
1:50pm - 2:00pm
Tech Showcase
2:00pm - 2:10pm
Super-Charging CHO Cell Productivity using 2G UNic® Technology and Transposon Innovation
The realization of patient-driven benefits from complex biologics remains a significant challenge, primarily due to high cost of goods. ProteoNics addresses this bottleneck by integrating its proven 2G UNic® vector technology with advanced transposon systems to achieve sky-high expression titres.
This powerful combination, along with further improvements in development and manufacturing, paves the way for next-generation biologics to be produced at significantly lower cost. Selection can be completed in just two weeks, yielding bulk pools enriched with high-expressing clones. This enables a faster, more efficient, and more robust clone selection process, accelerating timelines and reducing costs without compromising quality.
- Maurice Van Der Heijden - Senior Director, Research and Development, ProteoNic
1:00pm - 1:45pm
Lunch and Sponsor Presentations
1:45pm - 2:10pm
Stakeholder Roundtable Discussions: Part 2 - Brainstorming Possible Solutions (Roundtable Topics to be Determined)
1:00pm - 1:10pmLive Lab
Collect Headsets
1:10pm - 1:20pmLive Lab
Live Lab MilliporeSigma
1:20pm - 1:30pmLive Lab
Live Lab CPC Colder Products
1:30pm - 1:40pmLive Lab
Live Lab Tosoh
1:40pm - 1:50pmLive Lab
Live Lab Lisure
1:50pm - 2:00pmLive Lab
Live Lab Ecolab
2:00pm - 2:10pmLive Lab
Live Lab Tour 6
Showing 10 of 10 Streams
Cell Line Development & Engineering
Cell Culture & Upstream Processing
Downstream Processing
Manufacturing Strategy & Digitalization
Analytical, Quality and Characterization
Development of Emerging Cell & Gene Therapies
Cell Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
Innovation and Community Stage (Exhibit Hall)
BioInnovation Group's Executive Summit
2:10pm - 2:15pm
Chairperson Remarks: Cell Line Development & Engineering
2:15pm - 2:45pm
13 C Metabolic Flux Analysis (MFA) of CHO cells utilizing various media and feed packages to elucidate metabolic bottlenecks
- Lorena Pena - Scientist, Bristol-Myers Squibb
2:45pm - 3:15pm
Optimizing Vector Design to Enhance Expression and Quality of Bispecific Antibodies
- Fernanda Sobreira - Associate Principal Scientist, Merck
2:10pm - 2:15pm
Chairperson Remarks: Cell Culture & Upstream Processing
2:15pm - 2:45pm
Leveraging Capacitance in Perfusion Bioreactors in the Generation2 Ambr(R) 250 High Throughput
- Lorraine Peters - Associate Scientist, AstraZeneca
2:45pm - 3:15pm
Scale-Down Model Qualification and Process Characterization Utilizing the Second-Generation Ambr® 250 High Throughput Mini Bioreactor System
- Coral Fung Shek - Process Development Senior Scientist, Amgen
2:10pm - 2:15pm
Chairperson Remarks: Downstream Processing
- Xuan Han, PhD - Senior Scientist, Amgen
2:15pm - 2:45pm
Modernizing the design of convective chromatography tools and processes for high-productivity mAb and Viral Vector purification
- Stefano Menegatti - Professor, Chemical and Biomolecular Engineering, North Carolina State University
2:45pm - 3:15pm
Case Study and Development Overview of Recovery and Downstream Challenges from Harvest to UF/DF for an Antibody in Accelerated Development
- Chase Herman, Ph.D. - Investigator, GSK
2:10pm - 2:15pm
Chairperson Remarks: Manufacturing Strategy & Digitalization
2:15pm - 2:45pm
CMC in the Age of Personalized Medicine: Meeting the Unique Challenges of Small Batch Manufacturing
- Gregory Zarbis-Papastoitsis, Ph.D - Chief Process and Manufacturing Officer, Ankyra
2:45pm - 3:15pm
CMC Regulatory Filings for NCE’s – How to Develop Module 3 for the FDA and the EU/UK without constraining Development Efforts
- Jack Greene - Chief Technical and Manufacturing Officer, JucaBio
3:15pm - 3:45pm
Sponsored Presentation: Building a Sustainable Future for Biomanufacturing
2:10pm - 2:15pm
Chairperson Remarks: Analytical, Quality and Characterization
2:15pm - 2:45pm
Innovative Approaches to Potency & Stability: Overcoming Analytical Drug-Delivery Challenges
- Arvind Srivastava, Ph.D. - Senior Vice President, ThirdArcBio
2:45pm - 3:15pm
Emerging Technologies & Bioassay Innovations: Bridging the Gap Between Development and Compliance
- Anand Srinivasan - Vice President of Technology and Innovations, and Head of the Center for Innovations and Biodesign, BioBridge Global
2:10pm - 2:15pm
Chairperson’s Opening Remarks: Development of Emerging Cell & Gene Therapies
2:15pm - 2:45pm
Case Study from Editas Medicine
2:45pm - 3:15pm
Prime Editor Lipid Nanoparticles: From Development to Scalable Manufacturing
- Weiyi Li - Senior Manager, LNP Formulation, Prime Medicine, Inc.
2:10pm - 2:15pm
Chairperson’s Opening Remarks: Cell Therapy Manufacturing & Analytics
- Shashi Prajapati - Director, Cell & Gene Therapies Analytical Development, Vertex Pharmaceuticals
2:15pm - 2:45pm
Advanced Analytical Strategies for Cell Therapy Product Characterization
- Lena Yang - Senior Scientist, Cell Therapy Analytical Development, Takeda
2:45pm - 3:15pm
Potency Assay for Commercial Product – Which One to Select?
- Therese Choquette - Head of Analytical and Translational Sciences, Tigen Pharma
2:10pm - 2:15pm
Chairperson’s Opening Remarks: Gene Therapy Manufacturing & Analytics
- David Dobnik - Research Councillor, National Institute of Biology
2:15pm - 2:45pm
Rapid Development of AAV Purification Process Without Sacrificing Recovery
- Hunter Reese - Scientist II, Asklepios Biopharmaceutical
2:45pm - 3:15pm
Maximizing Capsid Recovery: Optimizing Downstream Processing for Higher Yields
- Junfen Ma - Head of Genomic Medicine Purification Process Development, Sanofi
2:10pm - 2:50pm
Innovation Through Inclusion: Rewriting Leadership Pathways in Life Sciences
How Diverse Leadership Drives Breakthrough Innovation
In an industry built on scientific breakthroughs, our greatest innovation opportunity may be unlocking the full potential of diverse talent. While life sciences has made progress in improving diversity and hiring practices, the real advantage lies in creating inclusive pathways to leadership that harness different perspectives, experiences, and problem-solving approaches to drive the next generation of medical breakthroughs.
Discussion Points:
- Innovation Requires Inclusion
- How diverse leadership teams consistently outperform in R&D outcomes
- The competitive risk of homogeneous leadership in a global market
- Innovation Barriers
- Traditional career pathways limit the diversity in decision-making roles and the resulting innovation cost
- Why inclusive cultures are essential for creative risk-taking and breakthrough thinking
- Rewriting the Leadership Roadmap
- Creating pathways that value diverse experiences and non-linear career journeys and recognizes different styles and strengths
- Building mentorship programs that actively push diverse talent into decision-making positions
- The Future of Biotech Leadership
- Building organizations where innovation and inclusion are inseparable
- Measuring success beyond diversity metrics to innovation outcomes
- Dianne Keen Kim - President, Women in Bio
- Nicola Ambler - Co-Founder, CGT Circle
- Alicja Januszewicz - Former Head of HR, Marengo Therapeutics
2:50pm - 3:10pm
Tech Showcase
3:10pm - 3:40pm
Workforce Development: Growing Talent Pipelines and Creating Pathways to Careers in Life Sciences
A diverse and inclusive workforce is essential to the future of the life sciences industry, but too often, access to careers in this field remains out of reach for talented students from underrepresented backgrounds. Project Onramp is changing that by connecting Pell Grant-eligible undergraduates with paid summer internships that open doors to real-world experience, professional networks, and long-term career pathways. This panel will highlight how the program is building a stronger, more inclusive industry through partnerships with companies and students, featuring insights from interns, alumni, and host employers.
2:10pm - 2:55pm
Stakeholder Roundtable Discussions: Part 2 - Brainstorming Possible Solutions (Roundtable Topics to be Determined)
2:55pm - 3:10pm
Short Break
3:10pm - 3:45pm
Stakeholder Roundtable Discussions: Part 3 - Actionable Items (Roundtable Topics to be Determined)
Showing 4 of 4 Streams
Break
Innovation and Community Stage (Exhibit Hall)
Poster Viewing - Meet the Poster Presenters
BioInnovation Group's Executive Summit
3:45pm - 4:30pm
Afternoon Break
3:45pm - 4:30pm
Poster Viewing - Meet the Poster Presenters
Explore groundbreaking research and meet the poster presenters with your questions.
*For your poster to be entered into the poster competition, please submit your abstract by August 1, 2025 and PDF poster by August 22, 2025*
3:45pm - 4:10pm
Stakeholder Roundtable Discussions: Part 3 - Actionable Items (Roundtable Topics to be Determined)
4:10pm - 4:30pm
Short Break
Showing 10 of 10 Streams
Cell Line Development & Engineering
Cell Culture & Upstream Processing
Downstream Processing
Manufacturing Strategy & Digitalization
Analytical, Quality and Characterization
Development of Emerging Cell & Gene Therapies
Cell Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
Innovation and Community Stage (Exhibit Hall)
BioInnovation Group's Executive Summit
4:30pm - 5:00pm
A Comprehensive CHO Glycosylation Mutant Panel for Advancing Glycobiology and Therapeutic Protein Engineering
- Song Zhiwei - Senior Principal Scientist, Nexa Biologics
5:00pm - 5:30pm
Accelerating Biopharmaceutical Cell Line Selection with Label-Free Multimodal Nonlinear Optical Microscopy and Machine Learning
- Jindou Shi - PhD Student, GSK Center for Optical Molecular Imaging, UIUC
4:30pm - 5:00pm
Identifying upstream levers to improve monomer purity in antibody production
- Yingnan (Michael) Si - Scientist, Sanofi
5:00pm - 5:30pm
Fireside Chat: How do we go to the next level for Cell Culture and Upstream Development?
- Charles Sardonini, PhD - Consultant to the Biotechnology Industry, Sardonini Consulting, LLC
4:30pm - 5:30pm
PANEL DISCUSSION: Future Trends in Bioprocess Chromatography: Exploring Novel Technologies and Approaches
- Naveen Singh - Principal Scientist II, Process Development, Gilead
- Kabir Dhingra - Senior Scientist, Merck
4:30pm - 5:00pm
Creating a Winning Target Product Profile: A Roadmap for Successful Biopharmaceutical Development
- Regina Au - CEO, New Product Planning/Strategic Planning, BioMarketing Insight
5:00pm - 5:30pm
Overcoming Challenges in an ADC Process Performance Qualification Campaign
- Siu-Man (Kelvin) Lau - Principal Engineer, Abbvie
4:30pm - 5:00pm
Overcoming the Barriers to Further Adoption of MAM
- Hao Zhang - Sr. Principal Scientist, Amgen
5:00pm - 5:30pm
AI's Power in the Future of Process Analytical Technology (PAT)
- William Whitford - Founder, Oamaru BioSystems
4:30pm - 5:30pm
Panel Discussion: Cell and Gene Therapy CDMO Selection and External Manufacturing Best Practices
- Shankar Swaminathan, PhD - Team Lead, Associate Director Drug Product Development, Astellas Institute for Regenerative Medicine
- Jeff Masten - Senior Vice President CMC, Secretome Therapeutics
- Matthew Provencal - Executive Director Gene Therapy BDS Manufacturing, Sarepta
- Shawn Roach - Associate Principal Consultant, Regulatory CMC, Halloran
4:30pm - 5:00pm
Best Practices for Developing Robust Potency Assays for Cell Therapies
- Mariska ter Haak - Senior Director Analytical Development, IN8bio
5:00pm - 5:30pm
Analytical Development to Assess T Cell Therapy Product Potency: A Matrix Approach
- Dong Xu, Ph.D. - Associate Director, Cell Therapy Analytical Development, TScan Therapeutics
4:30pm - 5:00pm
Detectability and Propagation of MVM in HEK293 Cells: What it means for your Viral Safety Strategy
- Dana Schreffler - Sr. Manager QC Viral Safety, Regeneron
5:00pm - 5:30pm
Mastering hcDNA: A Harmonized CMC Approach in AAV Therapies
- Parag Kumthekar - Gene Therapy Downstream Process Development Lead, UCB Pharma
4:30pm - 5:00pm
PANEL: Latinos in Bio - Missed Opportunities: The Cost of Ignoring Diversity in Biotech Panel Overview
Join us for a compelling discussion featuring accomplished Latino leaders in biotechnology as they explore the critical importance of diversity in driving innovation, addressing health disparities, and creating a more inclusive industry landscape.
5:00pm - 5:30pm
Tech Showcase
4:30pm - 5:30pm
Stakeholder Roundtable Discussions: Recap from Each Group (Roundtable Topics to be Determined)
Showing 1 of 1 Streams
Break
5:30pm - 6:00pm
Transport for Biotech Week Boston Party from Boylston Street
6:00pm - 8:00pm
Innovation After Dark: Networking Party at the Museum of Science, Boston
8:00pm - 8:05pm
Close of Day Two
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams